RN-0361: An Investigational APOC3-Targeted siRNA Therapeutic for Hypertriglyceridemia

I. Executive Summary

RN-0361 is an investigational therapeutic agent currently under development by Rona Therapeutics Inc. It belongs to the class of small interfering RNA (siRNA) therapeutics, designed to specifically target Apolipoprotein C-III (APOC3) mRNA.[1] By employing the mechanism of RNA interference (RNAi), RN-0361 aims to reduce the hepatic production of APOC3 protein, a key regulator of triglyceride metabolism, thereby addressing conditions characterized by elevated triglyceride levels.[2] The primary indications being pursued include hypertriglyceridemia (HTG), severe hypertriglyceridemia (SHTG), mixed dyslipidemia, familial chylomicronemia syndrome (FCS), and hyperlipoproteinemia Type I.[1]

RN-0361 utilizes Rona Therapeutics' proprietary GAIA platform, an siRNA conjugate and oligo chemistry technology engineered to enhance stability and enable robust, durable, hepatocyte-specific gene silencing following subcutaneous administration.[1] This platform aims to optimize the therapeutic profile of the siRNA molecule.

Clinical development has progressed based on positive results from a Phase 1 single-dose clinical trial, which reportedly demonstrated a favorable safety profile and, significantly, a sustained reduction in triglyceride (TG) levels over a 6-month follow-up period.[1] These findings supported the clearance of an Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) in March 2025, permitting the initiation of Phase 2 clinical studies.[1] Rona Therapeutics is now planning a randomized, double-blind, placebo-controlled, multicenter global Phase 2 trial to further evaluate the efficacy, safety, and duration of effect of RN-0361 in the hypertriglyceridemia patient population over a nine-month period.[1] Based on the Phase 1 data, RN-0361 is positioned by its developer as a potential best-in-class APOC3-targeted siRNA, offering the prospect of durable efficacy and a patient-friendly subcutaneous dosing regimen.[1]

Table 1: RN-0361 Key Characteristics Summary

II. Mechanism of Action and Therapeutic Rationale

The therapeutic strategy underlying RN-0361 centers on the modulation of triglyceride metabolism through the targeted inhibition of Apolipoprotein C-III (APOC3). APOC3 is a well-established key regulator of triglyceride-rich lipoprotein metabolism. It primarily exerts its effects by inhibiting lipoprotein lipase (LPL) and hepatic lipase, enzymes crucial for the hydrolysis of triglycerides, and by impairing the hepatic uptake of triglyceride-rich lipoprotein remnants.[27] Elevated levels of APOC3 are strongly correlated with hypertriglyceridemia, a condition associated with increased risk of cardiovascular disease and acute pancreatitis.[27] Given that APOC3 is predominantly synthesized in hepatocytes, it represents an attractive target for liver-directed therapeutic interventions.[27]

RN-0361 is designed as a small interfering RNA (siRNA) therapeutic that leverages the natural biological process of RNA interference (RNAi).[1] siRNAs are short, double-stranded RNA molecules that can specifically bind to and promote the degradation of complementary messenger RNA (mRNA) sequences.[29] RN-0361 is engineered to target the mRNA encoding for APOC3 within hepatocytes.[1] Upon delivery to the liver cells, RN-0361 initiates the RNAi pathway, leading to the specific cleavage and degradation of APOC3 mRNA.[1] This targeted mRNA silencing effectively reduces the intracellular template available for APOC3 protein synthesis, resulting in a significant decrease in the production and secretion of APOC3 protein by the liver.[1]

The therapeutic rationale is that by substantially lowering circulating APOC3 levels, RN-0361 will alleviate the inhibition of LPL and hepatic lipase, thereby promoting the efficient clearance of triglycerides from the plasma.[27] This mechanism is expected to lead to a significant reduction in plasma triglyceride concentrations, addressing the core pathology of hypertriglyceridemia and potentially mitigating the associated risks of cardiovascular events and pancreatitis.[1]

A key technological component of RN-0361 is the utilization of Rona Therapeutics' proprietary GAIA platform.[1] This platform is described as encompassing siRNA conjugate and oligonucleotide chemistry technologies specifically designed to enhance the therapeutic properties of the siRNA molecule.[1] The stated goals of the GAIA platform are to achieve robust and durable gene silencing specifically within hepatocytes following subcutaneous administration.[1] This durability is reportedly achieved through "optimized chemical modifications" applied to the siRNA structure, likely aimed at increasing stability against nuclease degradation and ensuring prolonged intracellular activity.[1] The platform's emphasis on hepatocyte-specific delivery, likely via conjugation to a targeting ligand such as N-acetylgalactosamine (GalNAc) which binds to the asialoglycoprotein receptor highly expressed on liver cells (a common strategy for liver-directed siRNAs, though not explicitly stated for GAIA in the snippets), minimizes off-target effects and maximizes therapeutic concentration in the desired tissue.[1]

The development and capabilities of the GAIA platform appear closely linked to Rona Therapeutics' strategic acquisition of exclusive worldwide rights to Sanofi's siRNA platform in July 2022.[31] Sanofi's platform was noted for its novel nucleotide analogs and conjugation moieties that demonstrated enhanced stability and in vivo duration of action, aligning closely with the described attributes of GAIA.[31] This acquisition likely provided Rona with advanced, validated chemical modification and conjugation technologies, bolstering its internal capabilities and potentially accelerating the development of candidates like RN-0361. The integration of this technology into the GAIA platform underpins the claims of RN-0361's potential as a best-in-class agent, characterized by durable efficacy that could translate into a more convenient, less frequent dosing regimen compared to older therapeutic modalities.[1]

III. Clinical Development Program

The clinical evaluation of RN-0361 has progressed from preclinical stages through Phase 1 testing, leading to regulatory clearance for Phase 2 trials. While specific preclinical data for RN-0361 are not detailed in the available materials, Rona Therapeutics follows standard drug development pathways, as evidenced by mentions of preclinical data for other pipeline candidates like RN1871.[24]

Phase 1 Clinical Trial (Completed Single Dose Study)

Rona Therapeutics has reported the completion of a Phase 1 clinical trial involving a single dose of RN-0361.[1] This initial human study included a 6-month follow-up period to assess safety and pharmacodynamic effects.[1] Key findings from this trial, as reported by the company, include:

• Safety: RN-0361 demonstrated a favorable safety profile.[1] No specific adverse events were detailed in the provided sources.
• Efficacy (Pharmacodynamics): The trial showed a sustained reduction in triglyceride (TG) levels over the 6-month observation period following a single subcutaneous dose.[1] The magnitude of TG reduction was described as demonstrating "remarkable potency and durability".[2]

The observation of sustained TG lowering over six months after just one dose is a critical finding. It provides the primary clinical evidence supporting the potential for durable efficacy, a key characteristic enabled by the GAIA siRNA platform technology. This durability suggests the possibility of an infrequent dosing schedule (e.g., quarterly or potentially bi-annually, similar to goals for other advanced siRNA therapies like Rona's RN0191 [16]), which would offer significant convenience for patients compared to daily oral medications or more frequent injections. These positive Phase 1 results were pivotal in the decision to advance RN-0361 into Phase 2 development and underpin the company's positioning of the drug as a potential best-in-class therapeutic.[1]

Phase 1 Clinical Trial (NCT06471543 / RN0361-101)

Separate from the completed single-dose study, a Phase 1 trial for RN-0361 is registered on clinical trial databases under the identifier NCT06471543 (study ID RN0361-101).[2] Key details of this registered trial include:

• Design: Randomized, single-blinded, placebo-controlled study evaluating both single and multiple ascending doses.[2]
• Objectives: To evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of RN-0361.[2]
• Population: Approximately 60 adult subjects (aged 18-60 years) with elevated fasting serum triglycerides (> 80 mg/dL) and fasting LDL-C (≥70 mg/dL).[6]
• Status: Listed as "Not yet recruiting" as of mid-2024, with an estimated primary completion date of September 30, 2025.[6]

A discrepancy exists between the company's reports of a completed Phase 1 single-dose study providing the basis for the Phase 2 IND clearance [1] and the registration of this multiple ascending dose Phase 1 study (NCT06471543) as "not yet recruiting".[6] This suggests several possibilities: the completed study may have been conducted earlier, possibly in a different region (e.g., Australia, where Rona conducted Phase 1 for RN0191 [17]) under a different identifier, or NCT06471543 represents a subsequent Phase 1 study perhaps required alongside Phase 2 development or targeting slightly different parameters (like multiple dosing). Alternatively, there might be a lag in updating the trial registry status. Regardless, sufficient positive Phase 1 data exists to have secured FDA clearance for Phase 2 initiation.

Phase 2 Clinical Trial Initiation

Rona Therapeutics announced in March 2025 that the US FDA cleared its IND application for RN-0361, allowing the company to proceed with Phase 2 clinical trials in the United States.[1] The company is planning a pivotal Phase 2 study with the characteristics outlined in Table 2.

Table 2: Planned Phase 2 Trial Overview (Based on available data)

The initiation of this rigorously designed Phase 2 trial marks a significant advancement for RN-0361. Its global, multicenter nature will allow for evaluation in a diverse patient population. The focus on efficacy, safety, and particularly the nine-month duration assessment, underscores the objective to confirm the durable triglyceride-lowering effect observed in Phase 1, which is central to the drug's potential value proposition.[1]

IV. Developer Profile and Strategic Context

RN-0361 is being developed by Rona Therapeutics Inc., a Shanghai-based company positioning itself as a global leader in the field of RNA-targeted therapeutics, with a particular emphasis on siRNA technology.[1] The company's therapeutic focus spans metabolic diseases (including cardiovascular conditions like hypertriglyceridemia, hypercholesterolemia, hypertension, MASH, obesity, and kidney disease) and neurological disorders (such as ALS and Alzheimer's disease).[1] Rona utilizes both liver-targeted and extra-hepatic delivery platforms to address these areas, aiming to develop differentiated "best-in-class" and "first-in-class" siRNA medicines.[1]

Within Rona's publicly disclosed pipeline, RN-0361 represents the second program to enter clinical trials, following RN0191.[11] RN0191, an siRNA targeting PCSK9 for hypercholesterolemia, has completed Phase 1 studies in Australia and China and is reported to be ready for Phase 2 development.[11] The progression of RN-0361 into Phase 2 planning shortly after RN0191 indicates momentum in Rona's metabolic disease portfolio.

Regarding the origination of RN-0361, while Rona Therapeutics is the current developer actively advancing the program and is listed as the originator in some databases [2], other industry databases (AdisInsight, Pryzm) identify Ikaria Bioscience Pty Ltd as the originator.[3] Ikaria Bioscience is also listed as an active organization alongside Rona for RN-0361 in one source.[14] This suggests that RN-0361 may have been initially developed or discovered by Ikaria Bioscience and subsequently licensed or acquired by Rona Therapeutics. Rona's leadership is evident in the execution of the Phase 1 trial and the successful navigation of the FDA IND process for Phase 2.[1]

Rona Therapeutics' capacity to advance RN-0361 is supported by recent strategic activities. In July 2024, the company secured $35 million in Series A+ financing, explicitly intended to progress its leading metabolic siRNA programs, including RN-0361, into global clinical development and to expand its extra-hepatic delivery platforms.[17] Furthermore, the 2022 exclusive licensing agreement with Sanofi, which granted Rona rights to Sanofi's advanced siRNA platform technology and four preclinical liver-targeted programs, represents a significant technological and portfolio enhancement.[16] As discussed previously, this acquired technology likely forms the foundation of the GAIA platform applied to RN-0361, providing a validated technological basis for the drug's development and claims of enhanced stability and durability. These strategic investments and technology acquisitions underscore Rona's commitment to establishing a competitive position in the RNA therapeutics landscape and provide a robust foundation for the continued development of RN-0361.

V. Conclusion and Future Outlook

RN-0361 emerges from the available data as a promising investigational siRNA therapeutic targeting APOC3 for the management of hypertriglyceridemia and related lipid disorders.[1] Its mechanism of action, leveraging RNA interference to specifically silence APOC3 mRNA in the liver, offers a targeted approach to reducing triglyceride levels.[1] The reported positive outcomes from the initial single-dose Phase 1 trial, particularly the favorable safety profile and the sustained triglyceride reduction observed over a 6-month period, provide preliminary validation of its potential.[1]

The utilization of Rona Therapeutics' proprietary GAIA platform, likely enhanced by technology acquired from Sanofi, appears central to RN-0361's potential best-in-class profile, aiming for durable efficacy and hepatocyte specificity.[1] If confirmed in later-stage trials, this durability could translate into a significant clinical advantage through less frequent subcutaneous dosing, improving patient convenience and adherence compared to existing therapies.

The clearance of the IND by the US FDA in March 2025 marks a critical regulatory milestone, enabling the progression into a global, randomized, placebo-controlled Phase 2 trial.[1] This upcoming study will be crucial for rigorously evaluating the efficacy, safety, and long-term durability of RN-0361 in a larger, diverse patient population with hypertriglyceridemia. Positive results from this trial would substantially strengthen the evidence for RN-0361 as a valuable therapeutic option for addressing the significant unmet medical need in severe lipid disorders.[1] Clarification regarding the status and relationship between the completed single-dose Phase 1 study and the registered, not-yet-recruiting multiple-dose Phase 1 trial (NCT06471543) would provide a more complete understanding of the early clinical development pathway. Overall, RN-0361 represents a significant asset in Rona Therapeutics' pipeline, with the potential to offer an innovative, durable, and convenient treatment for patients with challenging lipid disorders.

Works cited

1. Rona Therapeutics Receives IND Clearance from FDA to Initiate Phase 2 Study of RN0361: an APOC3 Targeted siRNA for Management of Hypertriglyceridemia - FirstWord Pharma, accessed April 30, 2025, https://firstwordpharma.com/story/5942577
2. RN-0361 - Drug Targets, Indications, Patents - Patsnap Synapse, accessed April 30, 2025, https://synapse.patsnap.com/drug/a19005bbfc5948df96ecf1ace6c89a0c
3. RN 0361 - AdisInsight - Springer, accessed April 30, 2025, https://adisinsight.springer.com/drugs/800078929
4. Phase 2 study of RN0361 in hypertriglyceridemia patient population - AdisInsight - Springer, accessed April 30, 2025, https://adisinsight.springer.com/trials/700381150
5. Rona Therapeutics Receives IND Clearance from FDA to Initiate Phase 2 Study of RN0361: an APOC3 Targeted siRNA for Management of Hypertriglyceridemia - BioSpace, accessed April 30, 2025, https://www.biospace.com/press-releases/rona-therapeutics-receives-ind-clearance-from-fda-to-initiate-phase-2-study-of-rn0361-an-apoc3-targeted-sirna-for-management-of-hypertriglyceridemia/
6. Study of RN0361 in Adult Subjects - ClinicalTrials.Veeva, accessed April 30, 2025, https://ctv.veeva.com/study/study-of-rn0361-in-adult-subjects
7. RN0361 - Drug Targets, Indications, Patents - Patsnap Synapse, accessed April 30, 2025, https://synapse.patsnap.com/drug/c07dcee918654a28a522f5bacd8942c7
8. Trial details imported from ClinicalTrials.gov - ANZCTR - Registration, accessed April 30, 2025, https://dev.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=23219&isClinicalTrial=True
9. Rona Therapeutics Receives IND Clearance from FDA to Initiate Phase 2 Study of RN0361: an APOC3 Targeted siRNA for Management of Hypertriglyceridemia - PR Newswire, accessed April 30, 2025, https://www.prnewswire.com/news-releases/rona-therapeutics-receives-ind-clearance-from-fda-to-initiate-phase-2-study-of-rn0361-an-apoc3-targeted-sirna-for-management-of-hypertriglyceridemia-302402731.html
10. Rona gets FDA go-ahead for Phase 2 siRNA heart disease trial - Longevity.Technology, accessed April 30, 2025, https://longevity.technology/news/rona-gets-fda-go-ahead-for-phase-2-sirna-heart-disease-trial/
11. Rona Therapeutics Co.,Ltd - Drug pipelines, Patents, Clinical trials - Patsnap Synapse, accessed April 30, 2025, https://synapse-patsnap-com.libproxy1.nus.edu.sg/organization/320d53215d9fb839c98cf710814401a2
12. Rona Therapeutics Receives IND Clearance from FDA to Initiate Phase 2 Study of RN0361: an APOC3 Targeted siRNA for Management of Hypertriglyceridemia - BioSpace, accessed April 30, 2025, https://www.biospace.com/press-releases/rona-therapeutics-receives-ind-clearance-from-fda-to-initiate-phase-2-study-of-rn0361-an-apoc3-targeted-sirna-for-management-of-hypertriglyceridemia
13. RN-0361 Drug Profile - Ozmosi, accessed April 30, 2025, https://pryzm.ozmosi.com/product/rn-0361
14. Ikaria Bioscience Pty Ltd - Drug pipelines, Patents, Clinical trials - Patsnap Synapse, accessed April 30, 2025, https://synapse-patsnap-com.libproxy1.nus.edu.sg/organization/eb3040343d04b32c85b4839da7c8cea4
15. Rona Therapeutics Receives IND Clearance from FDA to Initiate Phase 2 Study of RN0361: an APOC3 Targeted siRNA for Management of Hypertriglyceridemia - PR Newswire, accessed April 30, 2025, https://www.prnewswire.com/apac/news-releases/rona-therapeutics-receives-ind-clearance-from-fda-to-initiate-phase-2-study-of-rn0361-an-apoc3-targeted-sirna-for-management-of-hypertriglyceridemia-302402740.html
16. AHA24: Rona's Sanofi-sourced siRNA shows early promise in dyslipidaemia, accessed April 30, 2025, https://firstwordpharma.com/story/5913264
17. Rona Therapeutics Raises $35 Million Series A+ Financing to Advance Innovative Metabolic siRNA Pipeline in Clinic and Next Generation RNA Platforms - Newswire.ca, accessed April 30, 2025, https://www.newswire.ca/news-releases/rona-therapeutics-raises-35-million-series-a-financing-to-advance-innovative-metabolic-sirna-pipeline-in-clinic-and-next-generation-rna-platforms-842569937.html
18. Rona gets FDA go-ahead for Phase 2 siRNA heart disease trial - Longevity.Technology, accessed April 30, 2025, https://longevity.technology/news/rona-gets-fda-go-ahead-for-phase-2-sirna-heart-disease-trial/amp/
19. RN-0361 - Drug Targets, Indications, Patents - Synapse, accessed April 30, 2025, https://synapse-patsnap-com.libproxy1.nus.edu.sg/drug/a19005bbfc5948df96ecf1ace6c89a0c
20. Rona Therapeutics, Inc. - Patsnap Synapse, accessed April 30, 2025, https://synapse.patsnap.com/organization/39b9d27d3fa92bbbced3e289a416739b
21. RN0361 / Ikaria Biosci, Rona Therapeutics - Larvol Delta, accessed April 30, 2025, https://delta.larvol.com/Products/?ProductId=5bd5a540-9810-4f12-b319-30755b1f0f90
22. APOC3 x PCSK9 - Drugs, Indications, Patents - Synapse, accessed April 30, 2025, https://synapse.patsnap.com/target/a92c2405aefd399ebb76a2429884ab64
23. Rona Therapeutics - The Bradford Era, accessed April 30, 2025, https://www.bradfordera.com/author/rona-therapeutics/
24. Rona Therapeutics Announces NMPA Approval of IND Application for RN1871, a Novel Angiotensinogen (AGT)-Targeting siRNA Drug for Hypertension - Newswire.ca, accessed April 30, 2025, https://www.newswire.ca/news-releases/rona-therapeutics-announces-nmpa-approval-of-ind-application-for-rn1871-a-novel-angiotensinogen-agt-targeting-sirna-drug-for-hypertension-868167497.html
25. Rona Therapeutics Announces NMPA Approval of IND Application for RN1871, a Novel Angiotensinogen (AGT)-Targeting siRNA Drug for Hypertension - PR Newswire, accessed April 30, 2025, https://www.prnewswire.com/apac/news-releases/rona-therapeutics-announces-nmpa-approval-of-ind-application-for-rn1871-a-novel-angiotensinogen-agt-targeting-sirna-drug-for-hypertension-302432291.html
26. Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions - Newswire.ca, accessed April 30, 2025, https://www.newswire.ca/news-releases/rona-therapeutics-presented-positive-phase-1-results-of-rn0191-a-novel-sirna-therapy-targeting-pcsk9-at-the-2024-american-heart-association-aha-scientific-sessions-811896696.html
27. APOC3 RNA silencing therapeutic safely lowers triglycerides - - PACE-CME, accessed April 30, 2025, https://pace-cme.org/news/apoc3-rna-silencing-therapeutic-safely-lowers-triglycerides/2455592/
28. Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 Randomized Clinical Trial - PubMed, accessed April 30, 2025, https://pubmed.ncbi.nlm.nih.gov/38583092/
29. FDA-Approved Drugs for Hematological Malignancies—The Last Decade Review - PMC, accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8750348/
30. Optimization of Lipid Nanoparticles for saRNA Expression and Cellular Activation Using a Design-of-Experiment Approach | Molecular Pharmaceutics - ACS Publications, accessed April 30, 2025, https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.2c00032
31. Rona Therapeutics Announces Exclusive Licensing Transaction from Sanofi for its Broad siRNA Therapeutic Portfolio and Technology Platform - PR Newswire, accessed April 30, 2025, https://www.prnewswire.com/news-releases/rona-therapeutics-announces-exclusive-licensing-transaction-from-sanofi-for-its-broad-sirna-therapeutic-portfolio-and-technology-platform-301591673.html
32. Rona buys siRNA platform, 4 preclinical liver drugs from Sanofi - Fierce Biotech, accessed April 30, 2025, https://www.fiercebiotech.com/biotech/chinas-rona-raises-stake-sirna-game-buying-platform-4-preclinical-liver-drugs-sanofi
33. Rona Therapeutics | Biotechnology | The Pharmaletter, accessed April 30, 2025, https://www.thepharmaletter.com/ones-to-watch/rona-therapeutics
34. Rona Therapeutics, Keymed Biosciences Team Up To Develop siRNA Drugs For Kidney Disease - GeneOnline News, accessed April 30, 2025, https://www.geneonline.com/rona-therapeutics-keymed-biosciences-team-up-to-develop-sirna-drugs-for-kidney-disease/